agents have been employed in an attempt to prevent the development of CMV infection and disease where either donor or recipient are seropositive. Four clinical strategies are proposed for the management of CMV disease: prophylaxis, suppression, preThere are four therapeutic approaches which can be used. These are: emptive therapy and treatment. The degree of risk of developing CMV disease and the safety profile of the Prophylaxis: Antiviral agents are administered to all BMT presently available drugs need to be considered when deciding on the most appropriate approach. We conrecipients at risk of developing CMV disease. Therapy is started prior to any detection of CMV. clude that a prophylactic strategy employing a drug with a safe toxicity profile followed by pre-emptive Suppression: Antiviral agents are administered to BMT recipients when CMV is detected from peripheral sites such treatment with an effective antiviral drug for failure of prophylaxis gives the best outcome in allogeneic HLA as in the urine or throat washings, but prior to the development of any clinical symptoms of CMV disease. matched bone marrow transplant recipients.
500 mg/m 2 three times a day from 5 days before transplant patients in the study. At engraftment, patients were randomised to receive either i.v. ganciclovir 5 mg/kg or placebo to 30 days after transplant followed by oral aciclovir 800 mg four times a day for a further 6 months; i.v. aciclovir twice a day for 5 days and then the same dose once a day until 100 days post-BMT. All patients who excreted CMV at the same dose from day Ϫ5 to day +30 followed by placebo for a further 6 months; or oral aciclovir 200 were removed from the study and treated with ganciclovir. Winston et al 12 randomised patients 7 days prior to bone (children) to 400 mg (adults) four times a day from day Ϫ5 to day +30 followed by placebo until 7 months marrow transplant to receive either i.v. ganciclovir 2.5 mg/kg three times a day or placebo. Since ganciclovir is post-transplant (control group). Patients developing CMV viraemia were, at the discretion of physician, treated myelosuppressive, prophylaxis was stopped on the day before transplantation and restarted at engraftment at a dose pre-emptively with ganciclovir with or without immunoglobulin.
of 6 mg/kg once a day for 5 days each week until day 120 post-transplant. For patients whose neutrophil counts fell Goodrich et al 11 administered i.v. aciclovir 500 mg/m 2 three times a day from the start of the pretransplant conbelow 1.0 ϫ 10 9 /l, prophylaxis with the study drug was temporarily discontinued. When the neutrophil counts ditioning regimen until myeloid engraftment to all the 23 Ganciclovir given for times daily was taken orally from the day of transplant until 14 days was not associated with clinical or endoscopic day 20. Ganciclovir prophylaxis restarted on day 21 until improvements when compared with the provision of day 84 at 5 mg/kg three times per week. Patients in the supportive care in patients with CMV gastrointestinal historical group did not receive prophylactic ganciclovir.
disease. 24 A European multicentre study comparing the In another historical controlled study, 14 CMV seroposiefficacy of ganciclovir with foscarnet for the treatment of tive patients were given ganciclovir pretransplant at a daily CMV disease is underway. dose 6 mg/kg from day Ϫ10 to day Ϫ4. All patients were then given intravenous aciclovir at a daily dose of 1.5 g/m 2 in four doses from 3 days pretransplant to 29 days postResults from studies transplant. From day +30 to day +90, intravenous ganciclovir was given at a daily dose of 6 mg/kg/day for 5 days CMV infection each week provided the absolute neutrophil count was greater than 1 ϫ 10 9 /l on 3 consecutive days. The historical In all the studies reviewed in this report, CMV infection was principally defined as the isolation of CMV from any control group received intravenous aciclovir prophylactically, but not ganciclovir.
site. Additionally, Winston et al 12 included a four-fold increase in CMV antibody titre or the presence of typical CMV inclusion bodies in a tissue specimen in their Suppression/pre-emptive therapy definition of CMV infection. The results of the four prophylaxis studies are summarGoodrich et al 15 monitored patients for CMV excretion. If CMV was detected in the blood, urine, throat washings or ised in Table 2 . These show that all the regimens studied were effective in reducing CMV infection. High dose i.v. bronchoalveolar lavage fluid, patients who had marrow engraftment were randomised to receive either placebo or aciclovir given from conditioning for a period of about 1 month reduced the CMV infection rate by approximately i.v. ganciclovir 5 mg/kg twice a day for 7 days and then the same dose once a day until 100 days post-BMT or until 15% from that of the control groups. 9, 10 Ganciclovir given prior to BMT and restarted again at the time of engraftment they were discharged from the hospital. All patients were given intravenous aciclovir at a dose of 500 mg/m 2 three reduced the incidence of CMV infection from 43% in the placebo group to 20% in the ganciclovir group. 12 The most times a day for a maximum of 30 days from transplantation.
significant reduction in the incidence of CMV infection was shown in the study by Goodrich et al. 11 This group showed that extending prophylaxis with i.v. aciclovir by adminisPre-emptive therapy tering ganciclovir from engraftment until 100 days post-BMT significantly reduced the incidence from 45% when Recipients of allogeneic bone marrow transplants who were seropositive for CMV or were receiving a graft from a only aciclovir was used to 3% when aciclovir and ganciclovir were used sequentially. The incidence of CMV infection CMV-positive donor were evaluated for the presence of pulmonary CMV by bronchoalveolar lavage on days 35 and was measured from the time of engraftment. Two patients excreted CMV prior to engraftment and were not included 49. 16 Patients in whom CMV was detected were randomised to receive ganciclovir or to be monitored without treatin the analysis. prevented. In that study, all patients who excreted CMV NA = not available.
while on prophylactic therapy were also treated preemptively with ganciclovir. Atkinson et al 13 and Von Bueltzingsloewen et al 14 also showed a reduction in CMV In another study, prophylactic aciclovir followed by gandisease from historical rates of 23% and 59% respectively ciclovir was again shown to significantly reduce the incito 0% and 2.5% in the patients given prophylactic aciclovir dence of CMV infection from a historical rate of 72% to and ganciclovir. Winston et al 12 showed that when gan-7.5%. 14 ciclovir was administered prior to BMT and again at engraftment, a significant reduction in the incidence of CMV disease from that observed in the control group could CMV disease be achieved. The results of the prophylaxis studies on the incidence of Pre-emptive treatment of patients who had CMV CMV disease are shown in Table 3 . detected in bronchoalveolar lavage at day 35 significantly Meyers et al 9 showed that aciclovir used alone and reduced the probability of CMV pneumonia from 70% in administered from conditioning until 30 days post-BMT the control group to 10% in the treated group. 16 This has reduced the incidence of CMV disease. In that study, CMV led to the widespread use of pre-emptive therapy with gandisease included CMV pneumonia, and the isolation of ciclovir. Goodrich et al 15 demonstrated that when ganciclo-CMV from biopsies taken from the gastrointestinal tract.
vir was administered to patients who excreted virus in This effect could not be confirmed in the study by Prentice blood, urine, throat washings and bronchoalveolar lavage, et al 10 because the incidence of CMV disease in the control treatment with ganciclovir reduced the incidence of CMV group was much lower than that reported by Meyers et al disease from 43% to 3%. However, both Goodrich et al 15 and Schmidt et al 16 showed respectively that 12% and 23% of patients who did not excrete CMV nevertheless Table 3 Effect of prophylaxis on the incidence of CMV disease developed CMV disease. In an open study, foscarnet given at a dose of
Ref. Prophylactic Proportions (%) with CMV disease
100 mg/kg/day cleared viraemia in seven out of 10 patients regimen and five patients remained disease free at a median of 7
100-120 days 180-210 days
months from the start of the treatment. 25 In another study, 25 patients were randomised to receive either ganciclovir or between groups was not demonstrated in the study by Prenb Pre-emptive treatment allowed. NA = not available.
tice et al, 10 a reduction at 210 days post-transplant was engraftment, 58% of ganciclovir recipients and 28% of placebo recipients experienced neutropenia which required the interruption of the study drug (P = 0.005). Von Bueltzingsloewen 14 also showed that, historically, fewer patients shown among the recipients of long-term prophylactic treatrequired platelet and red blood cell transfusion when ment with high dose i.v. aciclovir followed by oral aciclovir prophylactic aciclovir and ganciclovir were not adminisfor a total of 7 months. At the end of 100 days post-BMT, tered. Meyers et al 9 did not show any difference between the mortality rate was 28% in the control group and was i.v. aciclovir recipients and placebo recipients in the time reduced to 12% in the recipients of i.v. and oral aciclovir.
to leucocyte count recovery. There were no differences Mortality at the end of 210 days was reduced significantly between the two groups in the time to engraftment either. from 41% in the control group to 25% in the recipients of Prentice et al 10 did not show any significant differences in long-term prophylaxis. In contrast to the effect shown in the white blood cell count among any of the treatment reducing the incidence of CMV infection and disease, groups. Goodrich et al 11 were not able to show any reduction in mortality at either 100 days (19% in aciclovir recipients and 12% in recipients of aciclovir and ganciclovir) or 180 Discussion days (26% in aciclovir recipients and 30% in recipients of aciclovir and ganciclovir) post-transplant by administering high dose i.v. aciclovir prophylactically followed by gan-
The detection of CMV in urine and throat washings (CMV infection) has often been adopted as an indicator of the ciclovir when compared to administering aciclovir alone. In the historical controlled study, Von Bueltzingsloewen et efficacy of a prophylactic regimen in the management of CMV in bone marrow transplant patients. While a reduction al 14 reported a mortality rate of 45% in patients given aciclovir and ganciclovir prophylactically. The historical 1-of CMV infection is a good indication of anti-CMV potency, reductions in morbidity, ie CMV disease, and moryear mortality rate at that institute was 15%. The number of patients dying of microbial infections was similar in both tality have a greater significance to the clinical management of these patients. The various strategies which can be groups. The majority of patients who were receiving aciclovir and ganciclovir prophylaxis died of causes related to adopted for management of CMV in BMT patients are outlined in Table 6 . regimen-induced toxicity and chronic GVHD. Winston et al 12 studied the effect of administering i.v. ganciclovir prior Since the detection of CMV in the throat washings and urine has been shown to be a poor predictor of CMV disto transplant and again at engraftment and failed to show any significant reduction in mortality between ganciclovir ease, 27 it is essential that a drug should possess both efficacy and low toxicity for the suppression of CMV. Gan-(30%) and placebo (36%) recipients.
Goodrich et al 15 showed a significant reduction in morciclovir administered at the detection of CMV from urine, blood, bronchoalveolar lavage and throat washings signifitality rate at day 100 from 17% in the placebo recipients to 3% when CMV-excretion was treated with ganciclovir.
cantly reduced the incidence of CMV disease. 15 However, there is no available evidence which demonstrates that the There was no death due to CMV in the ganciclovir group, compared to six CMV-associated deaths in the placebo intervention based solely on the isolation of CMV from peripheral sites (ie in urine and throat washings) results in group.
A summary of the results from all the controlled studies a reduction in CMV disease. Detection of CMV in the blood and bronchoalveolar lavage has frequently been discussed is shown in Table 5 .
